Ana P. Castaño

Cancer Clinic — United States

Medicine · Health Sciences

25h-index10.5kcitations68works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(26), Photodynamic Therapy Research Studies(21), Nanoplatforms for cancer theranostics(18), Immunotherapy and Immune Responses(13), Immune Cell Function and Interaction(8)

Publications68 total

Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Clinical Cancer Research·2024Open Access
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Nature Communications·2023· 40 citedOpen Access
Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
2023Open Access
Supplementary Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
2023Open Access
Supplementary Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
2023Open Access
Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
2023Open Access
Abstract 556: Novel anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Cancer Research·2022· 4 cited
552 Amphiphile-peptide boosting with FMC63-binding surrogate peptide mimotopes induces activation and potent effector function in CAR-T cells targeting CD19
Regular and Young Investigator Award Abstracts·2021Open Access
Mesenchymal stromal cells expressing a dominant-negative high mobility group A1 transgene exhibit improved function during sepsis
Journal of Leukocyte Biology·2021· 4 citedOpen Access
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Science Translational Medicine·2021· 244 citedOpen Access
A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq
Molecular Therapy·2020· 107 citedOpen Access
Bispecific CAR T cells for multiple myeloma: natural ligand compared to tandem scFv design
The Journal of Immunology·2020· 3 cited
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
Journal for ImmunoTherapy of Cancer·2019· 272 citedOpen Access
Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors
Blood·2019
Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML)
Blood·2019· 8 cited
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Blood Advances·2019· 107 citedOpen Access
Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding
Journal of Biological Chemistry·2019· 51 citedOpen Access
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Clinical Cancer Research·2019· 80 citedOpen Access
Bispecific T-Cell Engager -Armored Chimeric Antigen Receptor T Cells Overcome Antigen Escape From EGFRvIII-Targeted Therapy For Glioblastoma
Neurosurgery·2019
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Nature Biotechnology·2019· 542 cited
page 1 of 4Next →

Frequent Co-authors

Michael R. Hamblin(25), Marcela V. Maus(15), Amanda A. Bouffard(12), Rebecca C. Larson(10), Paweł Mróz(9), Andrea Schmidts(9), Irene Scarfò(9), Bryan D. Choi(7), Matthew J. Frigault(7), Jeremy S. Duffield(5), Shuei‐Liong Lin(5), Tatiana N. Demidova(4), Brian T. Nowlin(4), Michael C. Kann(4), Maria L. Cabral(4), Kathleen Gallagher(4), Faten Gad(4), Touqir Zahra(4), Xiaoling Yu(3), Stefanie R. Bailey(3)